Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

June 8, 2020

Primary Completion Date

November 11, 2021

Study Completion Date

December 9, 2021

Conditions
Glomerulosclerosis, Focal Segmental
Interventions
DRUG

VX-147

Tablets for oral administration.

Trial Locations (44)

10029

Icahn School of Medicine at Mount Sinai, New York

11203

SUNY Downstate, Brooklyn

14201

Urban Family Practice, Buffalo

15224

Children's Hospital of Pittsburgh of UPMC, Pittsburgh

19140

Temple University Hospital, Philadelphia

20037

The George Washington University Medical Faculty Associates - Kidney Disease & Hypertension, Washington D.C.

20060

Howard University Hospital, Washington D.C.

27599

UNC Kidney Center Division of Nephrology & Hypertension, Chapel Hill

27704

Durham Nephrology Associates, PA, Durham

27710

Duke University School of Medicine - Duke Molecular Physiology Institute, Durham

28210

Tryon Medical Partners, Charlotte

29118

South Carolina Nephrology and Hypertension Center, Inc., Orangeburg

29425

Medical University of South Carolina, Charleston

30046

Georgia Nehphrology, Lawrenceville

30310

Morehouse School of Medicine, Grady Memorial Hospital, Atlanta

30329

Children's Healthcare of Atlanta, Atlanta

31201

Central Georgia Kidney Specialists PC, Macon

32789

Florida Premier Research Institute, Winter Park

33150

Kidney and Hypertension Specialists of Miami, Miami

35294

University of Alabama at Birmingham - The Kirklin Clinic, Birmingham

37232

Vanderbilt University VU, Nashville

38801

Nephrology and Hypertension Associates, LTD, Tupelo

49007

Paragon Health, PC d/b/a Nephrology Center, PC, Kalamazoo

63136

St Louis Kidney Care, St Louis

70121

Ochsner Medical Center - New Orleans, New Orleans

70808

Renal Associates of Baton Rouge, Baton Rouge

77054

Prolato Clinical Research Center, Houston

77095

Privia Medical Group, Houston

89106

Nevada Kidney Disease and Hypertension Centers, Las Vegas

92123

California Institute of Renal Research, San Diego

02118

Boston Medical Center, Boston

02215

Beth Israel Deaconess Medical Center, Boston

01107

Renal and Transplant Associates of New England, PC, Springfield

Unknown

Hopital Henri Mondor, Créteil

Hôpital Bicêtre AP-HP, Le Kremlin-Bicêtre

Bichat Hospital, Paris

Hopitaux Universitaires Est Parisien - Hopital Tenon, Paris

Service de Nephrologie - Hopital Universitaire Necker, Paris

Université Paris-Descartes / Hôpital Européen Georges Pompidou, Paris

University Hospitals of Leicester NHS Trust - Leicester General Hospital, Leicester

Barts Health NHS Trust, London

The Medicines Evaluation Unit, Manchester

King's College Hospital NHS Foundation Trust - Guthrie Clinic, Southwark

00917

GCM Medical Group, PSC, San Juan

All Listed Sponsors
lead

Vertex Pharmaceuticals Incorporated

INDUSTRY

NCT04340362 - Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis | Biotech Hunter | Biotech Hunter